NASDAQ

Mereo BioPharma Group plc - American Depositary Shares (MREO)

570 Thanks from members

Mereo BioPharma Group plc (MREO) faces a split market narrative: while advancing rare disease pipelines like setrusumab and alvelestat with partners, the stock battles severe downward pressure, a negative Wall Street consensus, and a NASDAQ delisting warning due to its sub-$1.00 price.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →